Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities
Health CareHealth Care Providers
  • Price (USD)74.58
  • Today's Change0.88 / 1.19%
  • Shares traded3.80m
  • 1 Year change+6.94%
  • Beta0.4821
Data delayed at least 15 minutes, as of Sep 27 2024 23:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Centene Corporation is a healthcare company. The Company provides services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. It provides a range of managed healthcare products and services, primarily through Medicaid, Medicare, and commercial products. Its segments include Medicaid, Medicare, Commercial and Other. It offers Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace and the TRICARE program. It also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Medicaid program provides health insurance to low-income families and individuals with disabilities. Medicare is a federal health insurance program for people ages 65 and over, which also covers people under 65 with certain disabilities and people with end-stage renal diseases.

  • Revenue in USD (TTM)157.75bn
  • Net income in USD2.82bn
  • Incorporated2001
  • Employees67.70k
  • Location
    Centene Corp7700 Forsyth BlvdST. LOUIS 63105-1807United StatesUSA
  • Phone+1 (314) 725-4477
  • Fax+1 (302) 655-5049
  • Websitehttps://www.centene.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chemed Corp2.34bn300.92m8.71bn15.09k30.387.4423.983.7319.7219.72153.0180.511.44133.4215.30154,805.9018.5719.5322.4924.6435.9634.6012.8812.601.73--0.008.156.064.909.175.801.466.10
Ensign Group Inc3.97bn225.40m8.72bn35.30k36.924.9628.722.203.903.9068.7529.050.9458--7.99112,397.305.396.456.437.8821.3622.325.696.48--354.480.08156.5623.2716.28-6.8028.624.405.02
Encompass Health Corp5.07bn409.00m9.42bn22.36k23.925.2511.621.864.013.8949.7818.280.8279--9.04226,825.008.656.3711.017.9495.4995.5810.459.16--5.900.517830.7810.412.3441.314.4916.60-10.42
Solventum Corp8.21bn1.06bn12.40bn22.01k11.024.077.691.516.136.1347.5016.600.58173.977.36372,926.807.50--8.72--56.98--12.89--0.958410.030.7434--0.8241--0.2234------
Davita Inc12.52bn859.62m13.86bn70.00k17.3621.927.321.119.409.40136.767.440.737171.095.81178,919.406.745.629.107.4532.7230.709.158.331.125.260.7876--4.571.2626.442.33-10.47--
Universal Health Services, Inc.15.02bn934.19m15.52bn73.35k16.862.3710.221.0313.6313.63218.7797.211.08--7.05204,737.606.826.448.077.63----6.316.551.176.910.40946.066.595.806.32-1.471.1714.87
Natera Inc1.36bn-292.12m15.65bn3.28k--18.54--11.50-2.47-2.4711.386.780.984115.014.57414,534.80-21.13-36.17-26.88-46.6053.8545.88-21.47-56.154.01--0.3032--31.9933.2620.63--58.81--
Tenet Healthcare Corp20.92bn2.76bn15.77bn78.14k5.974.503.590.754227.3227.32205.2636.270.74149.276.85267,659.7012.523.6118.255.0982.5882.9716.894.951.384.890.62060.007.172.3349.0241.424.01--
Quest Diagnostics Inc9.35bn836.00m17.41bn40.00k20.882.6013.181.867.417.4182.8959.610.684534.237.32233,650.006.369.287.4910.8132.9836.649.2912.970.9128.510.396325.07-6.384.20-9.773.401.277.43
Labcorp Holdings Inc12.49bn449.50m18.96bn67.00k42.212.3217.981.525.265.26146.6195.530.725419.345.82186,382.102.626.273.207.3728.0032.333.619.510.76996.400.391--2.511.42-62.16-16.403.62--
Molina Healthcare Inc37.41bn1.06bn21.14bn18.00k18.714.1617.060.565218.2718.27643.0182.082.59--13.322,078,167.007.377.6215.7816.8015.6815.992.843.04--14.490.32990.006.5612.5237.759.0622.87--
Humana Inc112.04bn1.71bn37.95bn67.60k22.782.3113.840.338814.0314.03917.62138.462.10----1,657,337.003.357.57--------1.593.35--6.690.435312.5414.5413.33-11.307.6510.4113.25
Centene Corp157.75bn2.82bn40.28bn67.70k14.151.439.880.25535.275.27293.8052.001.90--10.452,330,059.003.402.585.543.9910.9611.591.791.37--4.770.3910.006.5420.70124.7924.593.43--
Data as of Sep 27 2024. Currency figures normalised to Centene Corp's reporting currency: US Dollar USD

Institutional shareholders

44.67%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202458.60m10.98%
Capital Research & Management Co. (World Investors)as of 31 Mar 202426.95m5.05%
Fidelity Management & Research Co. LLCas of 31 Mar 202426.92m5.05%
BlackRock Fund Advisorsas of 31 Mar 202424.61m4.61%
SSgA Funds Management, Inc.as of 31 Mar 202423.44m4.39%
Wellington Management Co. LLPas of 31 Mar 202418.20m3.41%
Norges Bank Investment Managementas of 31 Dec 202317.86m3.35%
Harris Associates LPas of 31 Mar 202416.99m3.18%
Geode Capital Management LLCas of 30 Jun 202412.68m2.38%
Politan Capital Management LPas of 31 Mar 202412.14m2.27%
More ▼
Data from 31 Dec 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.